Who
Eric E. Poma
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Calidi Biotherapeutics; Director and Officer, Molecular Templates; VP - Business Development, CytRx Oncology.
In numbers
- Trades disclosed
- 34
- Buys
- 1
- Sells
- 0
- Bought
- $50K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 8 Aug 2006
- Last trade
- 17 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 | filing |
| 17 Aug 2026filed 19 Aug 2026 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 | filing |
| 3 Sep 2025filed 5 Sep 2025 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 | filing |
| 21 Aug 2025filed 25 Aug 2025 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —25,000 | filing |
| 21 Aug 2025filed 25 Aug 2025 | CLDI Calidi BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $50K25,000 at $2.00 | filing |
| 22 Apr 2025filed 25 Apr 2025 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —726,412 | filing |
| 23 Jan 2024filed 25 Jan 2024 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —23,333 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 27 Apr 2022filed 29 Apr 2022 | Molecular Templatesoption or derivative | SEC FORM 4 Code M | —6,831 at $0.00 | filing |
| 27 Apr 2022filed 29 Apr 2022 | Molecular Templatesoption or derivative | SEC FORM 4 Code M | —27,325 at $0.00 | filing |
| 27 Apr 2022filed 29 Apr 2022 | Molecular Templates | SEC FORM 4 Code M | $4,8506,831 at $0.71 | filing |
| 27 Apr 2022filed 29 Apr 2022 | Molecular Templates | SEC FORM 4 Code M | $19K27,325 at $0.71 | filing |
| 15 Feb 2022filed 17 Feb 2022 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 6 Jul 2021filed 7 Jul 2021 | Molecular Templatesoption or derivative | SEC FORM 4 Code M | —3,563 at $0.00 | filing |
| 6 Jul 2021filed 7 Jul 2021 | Molecular Templates | SEC FORM 4 Code M | $2,5303,563 at $0.71 | filing |
| 15 Feb 2021filed 17 Feb 2021 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 14 Feb 2020filed 18 Feb 2020 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —312,500 at $0.00 | filing |
| 15 Feb 2019filed 20 Feb 2019 | Molecular Templatesoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 26 Nov 2018filed 29 Nov 2018 | Molecular Templates | SEC FORM 4 Code M | $64K152,945 at $0.42 | filing |
| 26 Nov 2018filed 29 Nov 2018 | Molecular Templates | SEC FORM 4 Code M | $62K86,951 at $0.71 | filing |
News
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026CLDI · manilatimes.net · 19 Oct 2026Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Shares Down 0.4% – Here's What HappenedCLDI · tickerreport.com · 17 Oct 2026
0 headlines in the last 90 days name Eric E. Poma; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.